Prima BioMed replaces director


By Dylan Bushell-Embling
Thursday, 13 February, 2014

Prima BioMed (ASX:PRR) has added former investment banker Pete Meyers to its board as a non-executive director.

Meyers is currently CFO of TetraLogic Pharmaceuticals, where he led the execution of its IPO in December.

Before joining TetraLogic, Meyers was an investment banker. Notable roles in the industry include co-head of global healthcare investment banking at Deutsche Bank in New York. He also held various roles at Dillon, Read & Co and Credit Suisse First Boston.

“I believe Pete’s depth of experience in the US capital markets, his network in the biotech community and his expertise advising healthcare companies will serve Prima well,” Prima Chairperson Lucy Turnbull said.

Meyers will be replacing Dr Richard Hammel, who is stepping down from the board after serving since January 2005.

Prima BioMed (ASX:PRR) shares were trading 4.08% higher at $0.051 as of around 2 pm on Tuesday.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd